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The choice of antiretroviral therapy for those naïve to
therapy is vast, with over 30 drugs available for the
treatment of HIV disease. Although international and
national guidelines often give recommended preferred
choices for commencement of therapy, it is important
that treatment is always individualised. Therefore for the
individual patient, it may be necessary to utilise treat-
ments outside of the guidelines which too often refer to
the near perfect patient.
Choice of antiretroviral therapy must be based on sev-
eral factors. These would include comparative trials on
efficacy. However the toxicity of the agents both singly
and in combination may be the most important in indivi-
dualisation of therapy, due to patient wishes and asso-
ciated co-morbidities. The ability for the patient to comply
with therapy may be made easier with once daily therapy
although the role of single tablet regimens remains contro-
versial. Together efficacy, toxicity and adherence contri-
bute to the potency of the antiretroviral regimen, where
potency is defined as the ability to succeed.
Other factors have become increasingly important.
There are increasing reports of primary resistance in sev-
eral European areas, which clearly may impact on the
choice of therapy, particularly within the non-nucleoside
class. In addition, with an ageing HIV population includ-
ing those newly diagnosed, potential drug interactions will
become an increasingly important factor. In several coun-
tries the issue of cost has now become an essential driver
towards choice of therapy, particularly with the advent of
generic drugs.
The majority of individuals will receive two nucleoside
reverse transcriptase inhibitors in combination with either
a ritonavir boosted protease inhibitor, a non-nucleoside
reverse transcriptase inhibitor most commonly efavirenz,
or an integrase inhibitor.
A recent large scale study performed by the ACTG,
suggested that overall success may be higher with an
integrase inhibitor, when compared with a ritonavir
boosted protease inhibitor, but closer examination of
these results shows that this was mostly driven by toxici-
ties associated with the protease inhibitors and a switch
from these drugs was not associated with a lower rate of
long-term success.
Several studies have examined novel treatments include
nucleoside sparing regimens. A recent study from the
NEAT Network suggested that a combination of raltegra-
vir, ritonavir and darunavir performed as well as a combi-
nation of truvada, ritonavir and darunavir. Again closer
inspection of these results would suggest that the nucleo-
side sparing regimen did not perform as well when stressed
both at high viral load and low CD4 count.
The initial choice of antiretroviral therapy is perhaps
one of the most important choices for the patient to
make. This should never be rushed, should be performed
within a partnership of patient and physician, and should
always reflect the needs of the individual patient not the
prescribing physician.
Published: 23 May 2014
doi:10.1186/1471-2334-14-S2-S3
Cite this article as: Nelson: First Line Therapy in 2014. BMC Infectious
Diseases 2014 14(Suppl 2):S3.
Chelsea and Westminster Hospital, Department of HIV and Genitourinary
Medicine, London, UK
Nelson BMC Infectious Diseases 2014, 14(Suppl 2):S3
http://www.biomedcentral.com/1471-2334/14/S2/S3
© 2014 Nelson; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
